Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

USFDA accepts for review Dr Reddy's biologics license application for Orencia biosimilar DRL_AB Swati Bharadwaj Hyderabad: Dr Reddy’s Laboratories Ltd.

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel ...

Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.

HIV status linked to distinct immune signatures tied to persistent portal hypertension after HCV cure in advanced cirrhosis.

Coherus BioSciences shows underwhelming LOQTORZI sales and reliance on upcoming pipeline catalysts. Read why CHRS stock is ...

Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow ...

By Vijay Kumar Malesu A pioneering personalized mRNA vaccine study reveals lasting immune responses in triple-negative breast cancer, offering early signals that tailored cancer vaccination may help ...

UCSF is teaming up with Nektar to study NKTR-0165, an experimental antibody that activates the TNFR2 receptor, as a treatment ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

Findings suggest engineered CD4+ T cells can modify Alzheimer's pathology and improve CNS immune responses, highlighting a novel therapeutic approach.